Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)

Trial Profile

A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NT 100 (Primary)
  • Indications Spontaneous abortion
  • Focus Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Nora Therapeutics

Most Recent Events

  • 01 Apr 2017 Status changed from active, no longer recruiting to completed.
  • 14 Jul 2015 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
  • 14 Jul 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top